Should you buy Repligen Corporation stock? (NasdaqGS:RGEN). Let's see how it does in our automated value investing analysis system.
(Repligen Corporation stock price per share)
||RGEN Fair Price
(based on intrinsic value)
|RGEN Safety Price (based on a variable margin of safety)||$8.38|
|PE Ratio versus Sector||291% higher than other Healthcare stocks|
|PE Ratio versus Industry||228% higher than other Medical Instruments & Supplies stocks|
|Free Cash Flow Jitter||89%|
This stock has short interest! This means that people have shorted it.
Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.
As of the latest analysis, there are 2,776,014 shares shorted. With 51,668,695 shares available for purchase and an average trading volume over the past 10 trading days of 452,270, it would take at least 6.138 days for all of the short holders to cover their shorts.
We believe that Repligen Corporation may be worth examining further. It's making money, which is a very positive sign. Is it on sale?
Repligen Corporation looks overpriced right now. If you're looking for a bargain in the stock market, you should probably look elsewhere for a great deal. This might still be a great stock to own—but it's not on sale right now.
Does Repligen Corporation have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.
Most Popular Articles